The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
rns http://investegate.co.uk/Article.aspx?id=201111250700217477S
extract from rhps Success could lead to a 4-fold increase in the share price So what are we looking at here? If these trials are successful, Synairgen is poised to make the move from being a pure research outfit to one that has genuine commercial potential. It has patented the use of inhaled IFN-β in the USA, the EU and Japan and has a licence and supply agreement for the manufacture of this patented formulation with Germany’s Rentschler Group. All it needs now is for these trials to be a success and it will then look to take these treatments forward in partnership with larger drug companies. From our point of view what matters is this: Successful trial results will show that Synairgen could have made a hugely valuable medical breakthrough in the treatment of viruses. RHPS Verdict: How much could success be worth? It is hard to say and is anyway dependent upon the exact details of the trial results. In 2009 I tipped Verona Pharma, also ahead of crucial test results. When these were positive the share price moved from 5.5p to a high of 19p. My target price of 100p for Synairgen would imply a value of £70m. For a genuine medical breakthrough with worldwide applicability against a range of viruses, that does not seem too fanciful. Let me stress again that this is high risk. If the test results come back negative I expect the share price to slump. But judging by Friday’s 6p jump in the share price the first test results could be imminent, and some are already prepared to bet that they will be good.
Positive results in viral pneumonia study for Synairgen's IFN-beta Southampton, UK - 25 November 2011: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company with a particular focus on viral defence of the lungs, is pleased to announce positive data from its pre-clinical study evaluating the effectiveness of aerosolised interferon beta ('IFN-beta') against viral pneumonia. Pneumonia is a major cause of morbidity and mortality and is most frequently caused by respiratory viruses; both highly pathogenic viruses such as influenza or SARS-like viruses and, in vulnerable populations, many other common respiratory viruses. Viral pneumonia results when infections spread to the lower respiratory tract and compromise lung function by damaging the cells that make up the air sacs (alveoli) and by causing leakage of fluid (oedema) and blood cells (haemorrhage) into the lungs. The effect of aerosolised IFN-beta was evaluated in a model of viral pneumonia caused by pandemic H1N1 ('swine flu'). Similar models have successfully predicted the clinical potential of antiviral therapies and vaccines. This study compared the potential use of aerosolised IFN-beta against placebo as either a pre-infection protective measure or as a post-infection treatment measure
http://investegate.co.uk/Article.aspx?id=201111250700217477S
think about it ? why spend three weeks to test a duster (not)
no confusion here definitely sey,been trading oil co for over 20 years
positive enough for me to hold until news is release probably next week IMHO
i would like to mention that a positive rumour regarding sterling is circulating amongst oil companies in Aberdeen. DYOR